Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Evaluation Study of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Subjects With Refractory Autoimmune Disease

NCT06925542 is registered in ClinicalTrials.gov with CRISPR Therapeutics as lead sponsor.

NCT NCT06925542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06925542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Evaluation Study of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Subjects With Refractory Autoimmune Disease
Lead sponsor
CRISPR Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
March 10, 2025
Completion date
December 31, 2031
Enrollment
80 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse cutaneous systemic sclerosis, inflammatory myopathy, idiopathic, lupus erythematosus, systemic, lupus nephritis, myositis, sle (systemic lupus), systemic sclerosis